A phase I trial of (90)Y-DOTA-anti-CEA chimeric T84.66 (cT84.66) radioimmunotherapy in patients with metastatic CEA-producing malignancies. [electronic resource]
Producer: 20060718Description: 88-100 p. digitalISSN:- 1084-9785
- Adult
- Aged
- Antibodies, Monoclonal -- adverse effects
- Carcinoembryonic Antigen -- biosynthesis
- Female
- Heterocyclic Compounds, 1-Ring -- adverse effects
- Humans
- Immunoglobulin G -- immunology
- Immunotoxins -- adverse effects
- Male
- Middle Aged
- Neoplasm Metastasis
- Neoplasms -- immunology
- Radioimmunotherapy -- adverse effects
- Yttrium Radioisotopes -- adverse effects
No physical items for this record
Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural
There are no comments on this title.
Log in to your account to post a comment.